FindTrial
Sign In

A Randomised Trial of Conformal versus Conventional Radiotherapy in Pelvic Neoplasms

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN17264730
Enrollment
Unknown
Registered
2002-08-19
Start date
2001-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer: Bladder (advanced), Bladder (superficial), Multiple Sites, Prostate, Rectum Cancer Bladder

Interventions

1. Group A: Conventional radiotherapy using a three field technique employing rectangular fields. Suggested dosage, 64 Gy in 2 Gy fractions five times a week 2. Group B: Conformal radiotherapy using

Sponsors

The Institute of Cancer Research (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Carcinoma of the pelvic region (eg prostate, bladder, rectum, etc) 2. Patients scheduled to undergo pelvic radiotherapy by a CT planned technique with less than four fields provided a satisfactory localisation on the simulator can be achieved

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026